Cannara Biotech Stock Working Capital
| LOVE Stock | CAD 0.75 0.05 6.25% |
Cannara Biotech fundamentals help investors to digest information that contributes to Cannara Biotech's financial success or failures. It also enables traders to predict the movement of Cannara Stock. The fundamental analysis module provides a way to measure Cannara Biotech's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Cannara Biotech stock.
| Last Reported | Projected for Next Year | ||
| Net Working Capital | 35.1 M | 20.9 M | |
| Change In Working Capital | -5.5 M | -5.8 M |
Cannara | Working Capital |
Cannara Biotech Company Working Capital Analysis
Cannara Biotech's Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .
More About Working Capital | All Equity Analysis
Working Capital | = | Current Assets | - | Current Liabilities |
Current Cannara Biotech Working Capital | 30.51 M |
Most of Cannara Biotech's fundamental indicators, such as Working Capital, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Cannara Biotech is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Cannara Working Capital Driver Correlations
Understanding the fundamental principles of building solid financial models for Cannara Biotech is extremely important. It helps to project a fair market value of Cannara Stock properly, considering its historical fundamentals such as Working Capital. Since Cannara Biotech's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Cannara Biotech's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Cannara Biotech's interrelated accounts and indicators.
Click cells to compare fundamentals
Working Capital can be positive or negative, depending on how much of current debt the company is carrying on its balance sheet. In general terms, companies that have a lot of working capital will experience more growth in the near future since they can expand and improve their operations using existing resources. On the other hand, companies with small or negative working capital may lack the funds necessary for growth or future operation. Working Capital also shows if the company has sufficient liquid resources to satisfy short-term liabilities and operational expenses.
| Competition |
Cannara Capital Lease Obligations
Capital Lease Obligations |
|
Based on the company's disclosures, Cannara Biotech has a Working Capital of 30.51 M. This is 92.83% lower than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The working capital for all Canada stocks is 97.94% higher than that of the company.
Cannara Working Capital Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Cannara Biotech's direct or indirect competition against its Working Capital to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Cannara Biotech could also be used in its relative valuation, which is a method of valuing Cannara Biotech by comparing valuation metrics of similar companies.Cannara Biotech is currently under evaluation in working capital category among its peers.
Cannara Biotech Current Valuation Drivers
We derive many important indicators used in calculating different scores of Cannara Biotech from analyzing Cannara Biotech's financial statements. These drivers represent accounts that assess Cannara Biotech's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Cannara Biotech's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 67.8M | 130.1M | 118.4M | 61.2M | 70.4M | 128.1M | |
| Enterprise Value | 72.9M | 142.8M | 154.6M | 103.0M | 118.4M | 143.2M |
Cannara Fundamentals
| Return On Equity | 0.0678 | ||||
| Return On Asset | 0.0378 | ||||
| Profit Margin | 0.07 % | ||||
| Operating Margin | 0.08 % | ||||
| Current Valuation | 113.72 M | ||||
| Shares Outstanding | 90.02 M | ||||
| Shares Owned By Insiders | 49.42 % | ||||
| Number Of Shares Shorted | 10 | ||||
| Price To Book | 0.82 X | ||||
| Price To Sales | 0.94 X | ||||
| Revenue | 57.26 M | ||||
| Gross Profit | 17.33 M | ||||
| EBITDA | 14.29 M | ||||
| Net Income | 6.95 M | ||||
| Cash And Equivalents | 5.56 M | ||||
| Cash Per Share | 0.01 X | ||||
| Total Debt | 5.97 M | ||||
| Debt To Equity | 0.45 % | ||||
| Current Ratio | 2.95 X | ||||
| Book Value Per Share | 0.91 X | ||||
| Cash Flow From Operations | 5.44 M | ||||
| Short Ratio | 0.03 X | ||||
| Earnings Per Share | 0.07 X | ||||
| Beta | 1.07 | ||||
| Market Capitalization | 72.02 M | ||||
| Total Asset | 141.52 M | ||||
| Retained Earnings | (19.34 M) | ||||
| Working Capital | 30.51 M | ||||
| Net Asset | 141.52 M |
About Cannara Biotech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Cannara Biotech's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cannara Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cannara Biotech based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Cannara Stock Analysis
When running Cannara Biotech's price analysis, check to measure Cannara Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cannara Biotech is operating at the current time. Most of Cannara Biotech's value examination focuses on studying past and present price action to predict the probability of Cannara Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cannara Biotech's price. Additionally, you may evaluate how the addition of Cannara Biotech to your portfolios can decrease your overall portfolio volatility.